Michael Gelband’s Denali Therapeutics DNLI Stock Holding History

Michael Gelband’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.66M	Buy	+336,567	New	+$6.92M	0.06%	331
2026 Q1	–	Sell	-1,023,253	Closed	-$16.9M	–	1673
2025 Q4	$16.9M	Buy	+1,023,253	New	+$17.3M	0.13%	130
2023 Q4	–	Sell	-17,381	Closed	-$359K	–	1589
2023 Q3	$359K	Buy	+17,381	New	+$441K	﹤0.01%	1361
2023 Q2	–	Sell	-24,907	Closed	-$574K	–	1935
2023 Q1	$574K	Buy	+24,907	New	+$685K	﹤0.01%	1300
2022 Q4	–	Sell	-23,434	Closed	-$719K	–	1736
2022 Q3	$719K	Sell	23,434 -40,753	-63%	-$1.32M	0.01%	1240
2022 Q2	$1.89M	Buy	+64,187	New	+$1.68M	0.02%	801
2021 Q3	–	Sell	-20,959	Closed	-$1.64M	–	2231
2021 Q2	$1.64M	Buy	+20,959	New	+$1.3M	0.02%	770
2020 Q4	–	Sell	-5,723	Closed	-$205K	–	2041
2020 Q3	$205K	Sell	5,723 -9,914	-63%	-$299K	﹤0.01%	1466
2020 Q2	$378K	Buy	+15,637	New	+$368K	0.01%	1202
2019 Q4	–	Sell	-10,000	Closed	-$153K	–	1606
2019 Q3	$153K	Buy	+10,000	New	+$191K	0.01%	1179
2019 Q2	–	Sell	-13,770	Closed	-$320K	–	1150
2019 Q1	$320K	Buy	+13,770	New	+$288K	0.02%	451

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's DNLI Position: Q2 2026 in Review

Michael Gelband opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 336,567 shares worth $8.66M. The stake represents 0.06% of the portfolio and ranks #331 among its holdings. This is a return to the name: Michael Gelband previously reported a position in DNLI as recently as Q4 2025.

Michael Gelband first reported a position in DNLI in Q1 2019 and has held it in 11 quarters since. The position peaked at $16.9M in Q4 2025. 290 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Michael Gelband held 336,567 shares of Denali Therapeutics worth $8.66M as of Q2 2026.
Denali Therapeutics was a new Michael Gelband position in Q2 2026.
Denali Therapeutics made up 0.06% of Michael Gelband's portfolio in Q2 2026, its #331 holding.
Michael Gelband first reported a position in Denali Therapeutics in Q1 2019 and has held it in 11 quarters since.
Michael Gelband's Denali Therapeutics position peaked at $16.9M in Q4 2025.
290 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.